Cimerli Injection, Solution
Product Images NDC 61314-625

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Cimerli (NDC 61314-625). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Cimerli 01)

An instructional illustration showing the correct method for withdrawing medication from a vial using a syringe. The first image shows the syringe needle inserted perpendicular into a vial, while the second image shows the needle inserted at an angle. The correct technique is indicated by the perpendicular insertion.*

FDA Label Image

Image (Cimerli 02)

An instructional illustration showing a syringe withdrawing solution from a vial. The vial has a rubber stopper, and an arrow indicates the direction of the syringe plunger being pulled up. The image depicts the preparation of an injectable medication, consistent with intravitreal injection procedures for products like CIMERLI (ranibizumab-eqrn).*

FDA Label Image

Image (Cimerli 03)

Illustration showing step-by-step instructions for assembling an injection syringe. The sequence includes removing a cap, twisting to attach a needle or component, and pulling off a protective cover, typically for preparing the ranibizumab-eqrn intravitreal injection.*

FDA Label Image

Image (Cimerli 04)

An instructional illustration showing a hand holding a syringe with a plunger being pushed or released by the other hand. The syringe appears to be prepared for injection, with the plunger partially depressed.*

FDA Label Image

Image (Cimerli 05)

Illustration of a syringe filled with 0.05 mL of solution, indicated by an arrow pointing to the 0.05 mL mark on the syringe barrel, showing precise measurement for injection.*

FDA Label Image

Figure 1 (Cimerli 06)

This image contains two line charts labeled AMD-1 and AMD-2 displaying mean change in visual acuity (letters) over 24 months. The lines compare treatments: ranibizumab 0.5 mg versus either sham or verteporfin PDT, showing visual acuity trends over time for each group.*

FDA Label Image

Figure 2 (Cimerli 07)

A line chart comparing mean change in visual acuity (letters) over 12 months between Ranibizumab 0.5 mg injection and a sham treatment. The graph shows visual acuity improvements with Ranibizumab and decline with the sham, plotting data points monthly with sample sizes of 61 and 63, respectively.*

FDA Label Image

Figure 3 (Cimerli 08)

A line graph titled 'AMD-4' depicting mean change in visual acuity over 24 months. It compares two groups treated with ranibizumab 0.5 mg: one receiving monthly injections and the other less frequent than monthly, showing visual acuity improvement in letters on the y-axis against months on the x-axis.*

FDA Label Image

Figure 4 (Cimerli 09)

A bar chart depicting the distribution of the number of intravitreal injections of CIMERLI (ranibizumab-eqrn) patients received. The x-axis represents the number of injections ranging from 0 to 21, and the y-axis shows the percentage of patients. The chart indicates variability with a mean of 10.3 injections.*

FDA Label Image

Figure 5 (Cimerli 10)

Two line graphs labeled RVO-1 and RVO-2 displaying mean change in visual acuity (letters) over six months. Each graph shows comparison between ranibizumab 0.5 mg and sham treatments with patients numbers indicated, illustrating greater improvement in visual acuity with ranibizumab than sham over time.*

FDA Label Image

Figure 6 (Cimerli 11)

Two line graphs labeled D-1 and D-2 showing mean change in visual acuity (letters) over 36 months. Each graph compares ranibizumab 0.3 mg injection to sham control, with a marked crossover from sham to ranibizumab after month 24. Data points are plotted monthly, illustrating visual acuity changes over time for both groups.*

FDA Label Image

Figure 7 (Cimerli 12)

Two bar charts display % of patients with ≥3-step and ≥2-step improvement from baseline over time, comparing Sham and 0.5mg Sham groups in D-1 and D-2 panels on the left, and 0.3mg Ranibizumab group on the right. The horizontal axis marks months 3, 6, 12, 18, 24, and 36; vertical axis shows percentage of patients up to 75%. P-values indicating statistical significance accompany bars.*

FDA Label Image

Figure 8 (Cimerli 13)

A bar chart comparing the percentage of eyes showing at least 3-step and 2-step improvement over Year 1 and Year 2, separated between eyes with baseline DME (n=41) and without baseline DME (n=148). The y-axis represents the percentage of eyes with upper 95% confidence intervals.*

FDA Label Image

Figure 9 (Cimerli 14)

A line graph depicting mean change in Best Corrected Visual Acuity (BCVA) from baseline over three months in letters on the ETDRS scale. It compares two ranibizumab treatment groups and a control group (vPDT) with data points at 0, 1, 2, and 3 months, showing improvement trends in the ranibizumab groups and little change in the control.*

FDA Label Image

0.3mg Vial Carton (Cimerli 15)

CIMERLI 0.3 mg injection label for ranibizumab-eqrn, a single-dose vial for intravitreal use. The label indicates one single-dose glass vial with prescribing information included. It states the product is intended for diabetic macular edema and diabetic retinopathy. Labeler is Sandoz Inc.*

FDA Label Image

0.5mg Vial Carton (Cimerli 16)

CIMERLI (ranibizumab-eqrn) injection label displaying a 0.5 mg single-dose vial for intravitreal use. The label indicates the vial contains one single-dose glass vial and prescribing information. It is for prescription use only and is manufactured by Sandoz Inc. The label also lists indications including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.